October 11, 2021 7:52am

Slips and dips have responded to what, the upcoming earning’s LPS (loss-per-share) season?

Pre-open indications: 1 BUY, 3 SELL and 1 Pump (or No Promote)

Remember that overnight and pre-open actions in futures doesn't necessarily translate into actual trading in the coming day’s session.

The U.S. bond market is closed Monday for Columbus Day.

Dow futures are DOWN -0.21% (-71 points), S&P futures are DOWN -37% (-16 point) and NASDAQ futures are DOWN -0.60% (-89 point)

 

Stock futures are in decline, Monday a.m. to start the week,

European stocks were subdued searching for direction after a volatile week,

Asia-Pacific stocks were mostly higher, with Hong Kong’s Hang Seng index jumping more than 2% to lead gains.

 

Henry’omics:

Friday finished near the flat line after investors shook off concerns about a much weaker-than-expected labor market report.

Quasi holiday but, there is the Boston Marathon that starts a mile away – it might start here but, we are blocked and “copped-off”

 

If you didn’t remember what happen at Friday night’s close and the quarter’s “number’s” impact, you won’t be prepared for today’s session:

  • Friday’s evening’s recap: “another stem, cell and gene therapy sector struggle as indexes dive. The knowns: volatility, lack luster sentiment, low volume = more uncertainty regarding inflation and rising rates as investors prepare for Q3 sector earnings” … https://www.regmedinvestors.com/articles/12131

Q4: October, 2 positive and 4 negative closes

Q3/21:

  • September, 1 holiday, 10 positive and 10 negative close
  • August - 12 positive and 10 negative close
  • July: 6 positives, 1 holiday and 15 negative closes

 

Companies in my headlights – It’s your decision; I provide an idea and context:

SELL with a Pump or no promote:

Biostage (BSTG) closed $0.00 (flat) with 32 shares traded following Thursday’s +$0.19 to $3.21 with 612 shares traded after Wednesday’s -$0.02 to $3.02, Tuesday’s -$0.59 following Monday’s +$0.59. For a company with NO clinical trial, an a one (1) and a half year approved IND, four (4) employees and NO CRO <clinical research organization> initiation.

What’s there to invest in – the “Sword of Damocles” hanging over its recent insurance company rejection of legal expense/costs of a terminal death suit against the company?

 

SELL:
CRISPR Therapeutics (CRSP) closed down -$4.36 to $98.63 after Thursday’s +$1.00 to $102.99, Wednesday’s -$0.50 to $101.99, Tuesday’s $102.49 and last Monday’s $102.43 with a negative -$0.63 or -0.64% pre-market indication.

Intellia Therapeutics (NTLA) closed down -$14.07 to $120.71 after Thursday’s +$5.09 to $134.78, Wednesday’s +$0.07 to $129.69, Tuesday’s +$2.98 to $129.76 and last Monday’s -$7.28 to $126.78, with a negative -$0.36 or +0.30% pre-market indication.

 

BUY:

Regenxbio (RGNX) closed down -$0.82 to $31.67 with a positive -$1.63 or +5.15% pre-market indication on news of initial data from the ongoing P2 ALTITUDE™ trial of RGX-314 for the treatment of diabetic retinopathy (DR) without center-involved diabetic macular edema (CI-DME) using in-office suprachoroidal delivery.

 

Sell into Strength:

ReNeuron (RENE.L) closed up on Friday +$2.30 after Thursday’s +$1.50 and Wednesday’s +$1.00) wit a positive +$33.20 or +35.02% on news of a nine-patient P2a (2m cell dose) extension study (halted in June after a presumed eye infection case) has fully restarted with five patients left to treat. Two patients are scheduled for treatment in October. RENE.L expects to report some data by March 2022, which could potentially open the way to a crucial partnering deal. Full efficacy data at six months post-treatment should be available around the middle of 2022

 

The BOTTOM LINE: Don’t act …until you see the green of the upside, I am NOT taking any action until the market’s direction is confirmed as goes the stem cell and gene therapy sector.

Theme is too much uncertainty, what’s more likely to me is skepticism …

Sector stocks have traded choppily over the past several weeks as investors contemplated the implications of ongoing price increases (i.e., inflation) against a backdrop of decelerating economic growth.

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.